Scholarlink

Purpose <p>Infective endocarditis (IE) is a evolving disease with a shifting epidemiology and disease burden over time. This study aimed to compare the epidemiological and clinical aspects of IE over three time periods across eleven years.</p> Methods <p>This was a retrospective cohort, multicenter study conducted in Türkiye, comparing three periods: 2013–2016, 2017–2020, and 2021–2023. Epidemiological and microbiological characteristics, as well as patient outcomes, were analyzed and compared across these periods.</p> Results <p>A total of 1,044 patients diagnosed with IE were included. The median (Q1-Q3) age was 57 (44–68) years, with an increasing pattern (<i>p</i> &lt; 0.001). Throughout the study period, the prevalence of intracardiac devices increased, whereas the prevalence of degenerative and congenital heart diseases declined. Among all patients, the most frequently identified pathogens were staphylococci (36.4%), followed by streptococci (14.0%) and enterococci (11.9%). Throughout the three periods, there was a significant increase in staphylococci, with <i>S. aureus</i> emerging as the predominant pathogen in all type IE. The in-hospital mortality rate among all patients was 22.5%. Independent risk factors for in-hospital mortality included ≥ 65 age(OR = 1.9), chronic kidney disease (OR = 1.9), nosocomial acquisition (OR = 2.1), <i>Candida</i> spp. infection (OR = 2.9), prosthetic valve IE (OR = 1.9), vegetation size &gt; 15&#xa0;mm (OR = 1.6), and central nervous system emboli (OR = 2).</p> Conclusion <p>The epidemiology of IE is undergoing significant changes, leading to shifts in microbiological profiles and clinical presentations. Effective management of IE should be guided by established clinical guidelines while integrating up-to-date epidemiological data to ensure comprehensive and evidence-based patient care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epidemiological, clinical and microbiological aspects of infective endocarditis in Türkiye

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月14日

查看全文
  • Elif M. Saricaoglu,
  • Seniha Basaran,
  • Derya Seyman,
  • Merve Arslan,
  • Serpil Ozkan-Ozturk,
  • Yasemin Tezer-Tekce,
  • Yesim Uygun-Kizmaz,
  • Nuran Sari,
  • Denef Berzeg-Deniz,
  • Alpay Azap,
  • Serap Simsek-Yavuz,
  • Ozlem Kurt-Azap

摘要

Purpose

Infective endocarditis (IE) is a evolving disease with a shifting epidemiology and disease burden over time. This study aimed to compare the epidemiological and clinical aspects of IE over three time periods across eleven years.

Methods

This was a retrospective cohort, multicenter study conducted in Türkiye, comparing three periods: 2013–2016, 2017–2020, and 2021–2023. Epidemiological and microbiological characteristics, as well as patient outcomes, were analyzed and compared across these periods.

Results

A total of 1,044 patients diagnosed with IE were included. The median (Q1-Q3) age was 57 (44–68) years, with an increasing pattern (p < 0.001). Throughout the study period, the prevalence of intracardiac devices increased, whereas the prevalence of degenerative and congenital heart diseases declined. Among all patients, the most frequently identified pathogens were staphylococci (36.4%), followed by streptococci (14.0%) and enterococci (11.9%). Throughout the three periods, there was a significant increase in staphylococci, with S. aureus emerging as the predominant pathogen in all type IE. The in-hospital mortality rate among all patients was 22.5%. Independent risk factors for in-hospital mortality included ≥ 65 age(OR = 1.9), chronic kidney disease (OR = 1.9), nosocomial acquisition (OR = 2.1), Candida spp. infection (OR = 2.9), prosthetic valve IE (OR = 1.9), vegetation size > 15 mm (OR = 1.6), and central nervous system emboli (OR = 2).

Conclusion

The epidemiology of IE is undergoing significant changes, leading to shifts in microbiological profiles and clinical presentations. Effective management of IE should be guided by established clinical guidelines while integrating up-to-date epidemiological data to ensure comprehensive and evidence-based patient care.